The Laryngeal Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Laryngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Laryngeal Cancer. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Laryngeal Cancer and features dormant and discontinued products.
GlobalData tracks 103 drugs in development for Laryngeal Cancer by 75 companies/universities/institutes. The top development phase for Laryngeal Cancer is phase ii with 51 drugs in that stage. The Laryngeal Cancer pipeline has 100 drugs in development by companies and three by universities/ institutes. Some of the companies in the Laryngeal Cancer pipeline products market are: AstraZeneca, AbbVie and Merck.
The key targets in the Laryngeal Cancer pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274), and Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC 2.7.10.1).
The key mechanisms of action in the Laryngeal Cancer pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with 18 drugs in Phase III. The Laryngeal Cancer pipeline products include 17 routes of administration with the top ROA being Intravenous and 17 key molecule types in the Laryngeal Cancer pipeline products market including Monoclonal Antibody, and Small Molecule.
Laryngeal Cancer overview
Laryngeal cancer is a disease in which malignant (cancer) cells form in the tissues of the larynx. Most laryngeal cancers form in squamous cells, the thin, flat cells lining the inside of the larynx. Symptoms include persistent hoarseness, difficulty swallowing, sore throat, or a lump in the neck. Treatment involves a combination of surgery, radiation therapy, and chemotherapy. Early detection is crucial for better treatment outcomes.
For a complete picture of Laryngeal Cancer’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
